Standout Papers

Baricitinib in Patients with Refractory Rheumatoid Arthritis 2016 2026 2019 2022 446
  1. Baricitinib in Patients with Refractory Rheumatoid Arthritis (2016)
    Mark C. Genovese, Joel Kremer et al. New England Journal of Medicine

Citation Impact

1 from Science/Nature 120 standout
Sub-graph 1 of 18

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
2024 Standout
2 intermediate papers

Works of Marek Krogulec being referenced

Baricitinib in Patients with Refractory Rheumatoid Arthritis
2016 Standout
OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study
2015

Author Peers

Author Rheumatology Immunology EE Hematology Last Decade Papers Cites
Marek Krogulec 483 186 28 241 10 654
Hui Liu 2 12 38 722
C Ng 17 3 2 4 9 494
João Carlos Gomes 30 302
Nora A. McDonald 2 7 895
Takahiro Yamanaka 9 67 1 6 54 660

All Works

Loading papers...

Rankless by CCL
2026